Drug Profile

GS 3107

Alternative Names: GS-3107

Latest Information Update: 08 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilead Sciences
Class Antiretrovirals
Mechanism of Action Capsid protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I HIV-1 infections

Most Recent Events

16 Jul 2025 Phase-I clinical trials in HIV-1 infections (PO) before July 2025 (Gilead Sciences pipeline, July 2025)
16 Jul 2025 Adverse events and pharmacokinetics data from preclinical studies in HIV-1 infections released by Gilead Sciences (Gilead Sciences pipeline, July 2025)
16 Jul 2025 Gilead Sciences plans a phase II trial for HIV-1 infections (Combination therapy) (PO) in 2026 (Gilead Sciences pipeline, July 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com